Experimental lymphoma combo trial halted early – only 5 patients enrolled
NCT ID NCT05498220
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new combination of drugs (polatuzumab vedotin plus standard chemotherapy) for patients with diffuse large B-cell lymphoma that came back or didn't improve after initial treatment. The trial aimed to see if this mix could shrink tumors better than standard therapy. However, the study was stopped early after enrolling only 5 people, so we have very little information about how well it works or its safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Polatuzumab vedotin combined with rituximab, gemcitabine, dexamethasone, and cisplatin (PV-RGDP chemotherapy)
- What this could lead to
- If successful, this combination could improve response rates for patients whose lymphoma returned after initial treatment, potentially leading to better outcomes before or instead of a stem cell transplant.
- What could go wrong
- The trial was terminated early with only 5 participants, so results are very limited. The combination may not be more effective than standard therapy and could have significant side effects from the chemotherapy drugs.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27514, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Can an immune booster outsmart brain lymphoma?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can donor immune cells be engineered to fight blood cancer?
- Can a simple blood test spot lymphoma earlier?
- What happens years after CAR-T therapy? a study aims to find out